Pfizer CEO Albert Bourla said on Monday that a vaccine that targets the Omicron variant of COVID-19 will be ready in March, and the company has already begun manufacturing the doses.
“This vaccine will be ready in March. We [are] already starting manufacturing some of these quantities at risk,” he told CNBC.